Lior Carmon
Chief Investment Officer bij Van Leer Xenia Ventures
Profiel
Lior Carmon is the founder of Vaxil Bio Ltd.
which was founded in 2006, where he held the titles of CEO, Director, and Head-Research & Development.
He is currently a Director at Israel Immunological Society, Saqura Bio Ltd.
(since 2022), and Chief Investment Officer at Van Leer Xenia Ventures.
Dr. Carmon's former position was as a Director at Vaxil Bio Ltd.
Dr. Carmon holds an MBA from Ben-Gurion University of the Negev and a doctorate from Weizmann Institute of Science.
Actieve functies van Lior Carmon
Bedrijven | Functie | Begin |
---|---|---|
Israel Immunological Society | Directeur/Bestuurslid | - |
Van Leer Xenia Ventures
Van Leer Xenia Ventures Investment ManagersFinance Van Leer Xenia Ventures (Van Leer Xenia Ventures) is a venture capital firm founded in 2006. The firm is headquartered in Jerusalem, Israel. | Chief Investment Officer | - |
Sakura Bio
Sakura Bio BiotechnologyHealth Technology Sakura Bio is a start-up company based in Jerusalem, Israel. Sakura Bio is developing an off-the-shelf, allogeneic T-cell therapy to fight cancer. The Israeli company's lead product, SAK-T (Super Activated Killer T-cell), is a unique T-cell population with superior anti-tumor cytotoxic activity and no toxicity of healthy tissue. The company was founded by Dikla Berko-Ashur and Amnon Peled, with Dikla Berko-Ashur serving as CEO since incorporation. | Directeur/Bestuurslid | 01-10-2022 |
Eerdere bekende functies van Lior Carmon
Bedrijven | Functie | Einde |
---|---|---|
VAXIL BIO LTD. | Directeur/Bestuurslid | 04-01-2017 |
Vaxil Bio Ltd. /Old/
Vaxil Bio Ltd. /Old/ BiotechnologyHealth Technology Vaxil Bio Ltd. is a clinical stage biotechnology company which engages in the development of synthetic therapeutic and preventive vaccines. It operates through the Cancer and Tuberculosis therapeutic areas. The Cancer area comprises vaccines for metastatic breast cancer patients in combination with hormonal therapy. The Tuberculosis area involves vaccines to boost immunity in BCG immunized patients and as a theraputic vaccine in TB patients. The company was founded by Lior Carmen and Julian Levy on August 6, 2006 and is headquartered in Nes-Ziona, Israel. | Algemeen Directeur | - |
Opleiding van Lior Carmon
Ben-Gurion University of the Negev | Masters Business Admin |
Weizmann Institute of Science | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
VAXIL BIO LTD. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Vaxil Bio Ltd. /Old/
Vaxil Bio Ltd. /Old/ BiotechnologyHealth Technology Vaxil Bio Ltd. is a clinical stage biotechnology company which engages in the development of synthetic therapeutic and preventive vaccines. It operates through the Cancer and Tuberculosis therapeutic areas. The Cancer area comprises vaccines for metastatic breast cancer patients in combination with hormonal therapy. The Tuberculosis area involves vaccines to boost immunity in BCG immunized patients and as a theraputic vaccine in TB patients. The company was founded by Lior Carmen and Julian Levy on August 6, 2006 and is headquartered in Nes-Ziona, Israel. | Health Technology |
Israel Immunological Society | |
Van Leer Xenia Ventures
Van Leer Xenia Ventures Investment ManagersFinance Van Leer Xenia Ventures (Van Leer Xenia Ventures) is a venture capital firm founded in 2006. The firm is headquartered in Jerusalem, Israel. | Finance |
Sakura Bio
Sakura Bio BiotechnologyHealth Technology Sakura Bio is a start-up company based in Jerusalem, Israel. Sakura Bio is developing an off-the-shelf, allogeneic T-cell therapy to fight cancer. The Israeli company's lead product, SAK-T (Super Activated Killer T-cell), is a unique T-cell population with superior anti-tumor cytotoxic activity and no toxicity of healthy tissue. The company was founded by Dikla Berko-Ashur and Amnon Peled, with Dikla Berko-Ashur serving as CEO since incorporation. | Health Technology |